N/A N=93 Exercise Regulation of Human Adipose Tissue
Healthy · Obese · Diabetes Mellitus, Type 2
Primary: Changes in Human Adipose Tissue Characteristics Following Exercise Training — 25.45; 34.12; 38.06; 27.05 body fat %
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)
Metabolic Diseases
Primary: Collection of Imaging of BAT by Magnetic Resonance Imaging — 78.69; 82.58; 82.45 Percentage
N/A N=20 Changes in Ectopic Fat Following Surgically Induced Weight Loss
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
Phase 2 N=48 Adipose Tissue Extract and Platelet-rich Plasma Use for Wound Healing
Wound Healing Disturbance of
Primary: Wound Re-epithelization — 12.34; 10.27; 11.33 days
N/A N=10 Circadian Brown Adipose Tissue Metabolism
Healthy
Primary: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
N/A N=69 Brown Adipose Tissue Activity in Pre- and Postmenopausal Women
Menopause · Obesity
Primary: Brown Adipose Tissue Volume — 53.1; 20.6 mL
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 3 N=326 Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
HIV Infections · Lipodystrophy
Primary: Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 — 0.5; -32.6 Square Centimeter (cm^2) — p=<0.001
Phase 4 N=38 Liraglutide Effects on Epicardial Fat Inflammatory Genes
Type2 Diabetes · Coronary Artery Disease
Primary: EAT Inflammation — 0.70; 1.4; 0.39; 0.25 ct (cycle threshold)
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
N/A N=5 Sympathetic Activation in Obesity
Obesity · Healthy
Primary: Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System — 0.13; -0.025; 0.095; -0.03 DVR
Phase 2 N=10 Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
Lipoma
Primary: The Average Percent Volume Reduction in the Lipoma. — 50 Percent Volume reduction (cc^3)
Phase 4 N=88 Optimizing Body Composition for Function in Older Adults
Obesity · Overweight With Indications for Weight Loss
Primary: Appendicular Non-bone Lean Mass — -2.53; -2.49; -2.04; -1.45 kg
N/A N=20 Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
Obesity, Visceral · Obesity; Endocrine
Primary: Visceral Fat Loss (cm3) — -628 cm3
N/A N=47 Antecedents of Obesity: Fetal Measures of Adiposity
Obesity
Primary: Infant Adiposity at 24-72 Hours Following Birth — 11 Percentage of total body weight
N/A N=33 The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Phase 3 N=59 Rosuvastatin in Visceral Adiposity
Abdominal Obesity
Primary: Change in Visceral Adipose Tissue Area Measured by Computed Tomography. — -1.5; 2.8 cm2
Phase 2 N=22 Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
N/A N=10 Measurement of Body Fat in Infants
Brown Adipose Tissue · Body Composition
Primary: Whole Body Fat Mass — 20.8 percentage of fat mass
N/A N=38 Strength Training for Skeletal Muscle Adaptation After Stroke
Stroke
Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs
N/A N=19 Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction
Body Fat Disorder
Primary: Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel…
N/A N=40 Assessment of Body Composition and Physical Function
Body Composition · Physical Function
Primary: Fat Mass — 44.71 Kg
N/A N=39 Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
Phase 2 N=103 Leptin to Treat Lipodystrophy
Lipodystrophy
Primary: Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin — 8.4; 8.1; 6.6; 7.2 percentage of glycated hemoglobin — p=<0.001
N/A N=112 A Cohort Study of Weight Loss and Gliosis
Obesity, Gliosis, Weight-Loss
Primary: Percent Change in Weight From Baseline — -6.1; -21.2; 1.2 percentage change from baseline — p=<0.001
N/A N=26 Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Trifunctional Protein Deficiency
Primary: An Outcome of This Study is the Difference in Percent Body Fat (%BF) Between Subjects With a Long-chain Fatty Acid Oxidation Disorder and Normal Controls. — 31.8; 27.2…
Phase 3 N=25 Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Hypoleptinemia · Generalized Lipodystrophy · Partial Lipodystrophy
Primary: Fasting Serum Triglycerides — 203; 304 mg/dL — p=0.2572